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It is well known that some algorithms recommend sec-
ond-generation antipsychotics as first line treatment. Such
recommendations are based on side-effect advantages and
on efficacy differences between first-generation (FGAs)
and second-generation antipsychotics (SGAs). Meta-anal-
ysis, which has been widely used in the medical ground
over the last decade, is a valuable tool to combine results
from several independent studies and, not only to draw
conclusions or evidence about a controversial field, but
also to serve as a process to solve disagreements among
studies. Therefore, summarizing the data from rand-
omized controlled trials and viewing it in a clinical frame-
work seems to serve as a useful and effective framework-
guide in the daily clinical practice. However, controversial
results of systematic reviews and meta-analysis often offer
nothing more than equivocate guidelines and usually
leave clinicians to decide on their own about which of
these results is the most appropriate for an optimal indi-
vidualized clinical intervention and which is the least.
Aripiprazole, a newly first dopamine D2 receptor partial
agonist, in a number of short-term trials has shown to sig-
nificantly reduce the negative and positive symptoms of
schizophrenia. Comparison of meta-analysis of mean
change in plasma prolactin, EPS, QTC prolongation and
somnolence level of aripiprazole with haloperidol, risp-
eridone and olanzapine ended in favor of aripiprazole.
We are going to review clinicians' data from clinical trials
on the efficacy and tolerability of the newer antipsychot-
ics. Clinicians can incorporate such data in their real-
world clinical practice for an effective and quality strategic
treatment approach.
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